Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

National accolade for Dr Philemon Akach
2013-10-21

 

Dr Philemon Akach
Photo: Sonia Small
21 October 2013


Excellence in Teaching and Learning is highly regarded at the University of the Free State, with our academics recognised on national and international platform.

Earning yet another accolade for the university, Dr Philemon Akach, Head of the Department of South African Sign Language, has been awarded a National Excellence in Teaching and Learning Award. The award by the Higher Education Learning and Teaching Association of Southern Africa (HELTASA) and Council on Higher Education (CHE), recognised Dr Akach as a “leader in the field of teaching and learning – with impact beyond the classroom and the institution.” Recognising his pioneering work within deaf education, HELTASA and CHE commend Dr Akach as an “inspirational practitioner who recognises the inclusion of the marginalised in education.”

Dr Akach is one of five recipients, selected out of a total of 22 candidates from across South Africa that will receive the award. The other winners are from the University of Cape Town, Stellenbosch University, University of KwaZulu-Natal and the University of Pretoria. The five winners will receive the awards at a gala dinner at the annual HELTASA conference, which takes place from 26 to 29 November 2013.

Dr Akach, who will retire at the end of 2014, says the national recognition is the cherry on top as he prepares to return to his home country. Kenya. “How good can it be?” “This is my life calling,” he said about the 37 years he worked within deaf education.

The academic also received an Alumni Award for Outstanding Service at the recent Kovsie Alumni Awards.

Pioneering work by Dr Akach:

  • With Dr Akach steering the process, the UFS became the first university on the continent to offer Sign Language as an academic course in 1999.
  • Dr Akach was part of a nine-member task team that handed over the South African Sign Language (SASL) curriculum to the Minister of Basic Education, Angie Motshekga. A member of the ministerial task team since 2009, he helped to coordinate the development of the curriculum that will soon be offered as a school subject to Grade 0–12 learners in all 42 schools for the deaf in South Africa.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept